Evercore ISI Lowers GoodRx (NASDAQ:GDRX) to Inline

GoodRx (NASDAQ:GDRXGet Rating) was downgraded by stock analysts at Evercore ISI from an “outperform” rating to an “inline” rating in a research report issued on Tuesday, Briefing.com reports. They currently have a $12.00 price target on the stock, down from their prior price target of $28.00. Evercore ISI’s price objective would indicate a potential upside of 11.63% from the company’s current price.

GDRX has been the subject of a number of other research reports. Robert W. Baird raised their price objective on shares of GoodRx from $17.00 to $23.00 in a research note on Tuesday, April 5th. Bank of America decreased their price objective on shares of GoodRx from $42.00 to $28.00 and set a “neutral” rating for the company in a research note on Tuesday, March 1st. Guggenheim initiated coverage on shares of GoodRx in a research note on Wednesday, April 6th. They set a “buy” rating and a $24.00 target price for the company. The Goldman Sachs Group decreased their target price on shares of GoodRx from $43.00 to $30.00 and set a “buy” rating for the company in a research note on Tuesday, March 1st. Finally, SVB Leerink decreased their target price on shares of GoodRx from $49.00 to $33.00 and set an “outperform” rating for the company in a research note on Tuesday, March 1st. One analyst has rated the stock with a sell rating, ten have issued a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, GoodRx has a consensus rating of “Hold” and a consensus price target of $26.56.

Shares of NASDAQ:GDRX opened at $10.75 on Tuesday. The company has a 50 day moving average price of $16.74 and a 200 day moving average price of $27.69. GoodRx has a 1-year low of $10.65 and a 1-year high of $48.05. The company has a debt-to-equity ratio of 0.79, a quick ratio of 13.42 and a current ratio of 13.42. The stock has a market capitalization of $4.31 billion, a price-to-earnings ratio of -153.55, a PEG ratio of 4.42 and a beta of 0.29.

GoodRx (NASDAQ:GDRXGet Rating) last posted its quarterly earnings data on Monday, May 9th. The company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.02. GoodRx had a negative net margin of 3.39% and a positive return on equity of 0.06%. The firm had revenue of $203.30 million during the quarter, compared to analyst estimates of $200.61 million. During the same quarter last year, the business posted ($0.01) EPS. The company’s revenue was up 26.7% on a year-over-year basis. On average, sell-side analysts expect that GoodRx will post 0.17 EPS for the current fiscal year.

Institutional investors have recently modified their holdings of the company. AdvisorNet Financial Inc boosted its holdings in GoodRx by 275.0% in the first quarter. AdvisorNet Financial Inc now owns 1,875 shares of the company’s stock valued at $36,000 after acquiring an additional 1,375 shares in the last quarter. IFP Advisors Inc lifted its position in GoodRx by 301.0% during the fourth quarter. IFP Advisors Inc now owns 1,163 shares of the company’s stock valued at $41,000 after buying an additional 873 shares during the period. First Horizon Advisors Inc. lifted its position in GoodRx by 208.2% during the third quarter. First Horizon Advisors Inc. now owns 1,350 shares of the company’s stock valued at $42,000 after buying an additional 912 shares during the period. CWM LLC lifted its position in GoodRx by 50.2% during the first quarter. CWM LLC now owns 2,224 shares of the company’s stock valued at $43,000 after buying an additional 743 shares during the period. Finally, Spire Wealth Management lifted its position in GoodRx by 50.0% during the fourth quarter. Spire Wealth Management now owns 1,500 shares of the company’s stock valued at $49,000 after buying an additional 500 shares during the period. Hedge funds and other institutional investors own 52.60% of the company’s stock.

GoodRx Company Profile (Get Rating)

GoodRx Holdings, Inc, through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.

See Also

Analyst Recommendations for GoodRx (NASDAQ:GDRX)

Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.